SynthesisFrontiers in pediatrics2025
Efficacy of glyburide vs. metformin in preventing neonatal birth obesity in pregnancies complicated by gestational diabetes mellitus: a systematic review and meta-analysis.
Synthesis in Frontiers in pediatrics, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Gestational diabetes: from pathogenesis to therapeutic intervention.Diabetology & metabolic syndrome · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Gestational diabetes mellitus (GDM) has significant implications for both maternal and fetal health, increasing the risk of macrosomia, neonatal hypoglycemia, and long-term metabolic complications in offspring. Given these concerns, a comprehensive evaluation of treatment options, including glyburide and metformin, compared to insulin, is essential to guide clinical practice. Methods: A systematic literature search was conducted following the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines, utilizing PubMed, EMBASE, and Web of Science without restrictions on date or language. The focus was on studies comparing oral medications (glyburide or metformin) with insulin for GDM, assessing outcomes, e.g., birth weight and the risk of macrosomia. Studies with non-relevant study designs were excluded. Data extraction and management were conducted with bias assessment using SYRCLE's tool. Statistical analyses were performed using R, incorporating both fixed and random effects models, subgroup analyses, and tests for publication bias. Results: This meta-analysis reviewed 23 studies (20 randomized controlled trials and 3 retrospective cohort studies) that evaluated treatments for GDM. The overall risk of macrosomia did not differ statistically between oral medications and insulin [odds ratio (OR) = 0.8534, 95% confidence interval (CI) (0.6271; 1.1614), Conclusion: This meta-analysis suggests that oral medications for GDM do not statistically alter the overall risk of macrosomia or infant birth weight compared with insulin administration. However, glyburide is associated with an increased risk of macrosomia, whereas metformin appears to reduce this risk. Consistent with these findings, glyburide was associated with an increase in infant birth weight, while metformin was associated with a decrease. These findings emphasize the importance of personalized treatment strategies for GDM management.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.